A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
PHASE2
This study is a randomized, controlled, open-label, multicenter, seamless P...
Phase Ib/II Multicenter Randomized Control Study of Peri-operative Treatment With Combination of CTLA-4, PD-1 Antibodies and Bevacizumab in Resectable HCC (Prophet)
PHASE1
The purpose of this phase Ib/II multicenter randomized control study is to ...
A Clinical Study to Observe the Effectiveness and Safety of IBI310, Bevacizumab Combined With Sintilimab in the Treatment of Advanced Hepatocellular Carcinoma
PHASE1
This is a randomized, open-label, multicenter Phase Ib study to evaluate th...